10-K/A: Coeptis Therapeutics Restates 2023 Financials Due to Accounting Error

Coeptis Therapeutics Holdings, Inc. has filed an amendment to its 2023 annual report to correct the classification of subscription receivables on its balance sheet.

Summary

• Coeptis Therapeutics Holdings, Inc. has amended its 2023 annual report on Form 10-K to reclassify subscription receivables.
• The reclassification was due to an evaluation of accounting for note agreements, which determined that notes receivable should have been recorded as subscription receivables.
• The company filed its original 10-K on March 25, 2024, and the amendment was filed on August 15, 2024.
• The company had a net loss of $21,266,537 for the year ended December 31, 2023, and an accumulated deficit of $87,356,260.
• As of March 22, 2024, the company had 36,089,917 shares of common stock outstanding.
• The company is an emerging growth company and has elected to take advantage of reduced disclosure requirements.
• The company has identified material weaknesses in its internal control over financial reporting and is working to remediate them.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a restatement, material weaknesses in internal controls, and a going concern warning. While there are some positive developments in product development, the overall sentiment is negative due to the financial instability and operational risks.

Positives

• The company is actively working to correct accounting errors and improve financial reporting.
• The company is pursuing strategic partnerships and collaborations to expand its product pipeline.
• The company has made progress in developing its CD38-GEAR-NK and CD38-Diagnostic programs.
• The company has secured an exclusive license for a stem cell expansion platform and acquired Phase 1 clinical trial programs.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has limited operating history and has generated minimal revenue to date.

Risks

• The company may not be able to successfully implement its growth strategy.
• The company may have difficulties managing its anticipated growth.
• The company may not be able to initiate and complete clinical trials for its product candidates.
• The company needs to obtain financing to continue its operations.
• The drug development and approval process is uncertain, time-consuming, and expensive.
• Competition in the biotechnology and pharmaceutical industries may result in lower revenues or profits.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company expects to continue to generate operating losses and experience negative cash flow from operations at least through the end of 2023 or longer. The company believes that the ability to raise capital through equity transactions will increase liquidity and enable the execution of managements operating strategy.

Management Comments

• Management determined the originally filed 10-K does not give full effect to the transactions, and the notes receivable should have been recorded as subscription receivables.
• Management believes that additional financing as necessary will result in improved operations and cash flow.

Industry Context

This announcement comes amid a challenging period for many biotech companies, which are facing increased scrutiny and funding difficulties. The restatement highlights the importance of robust internal controls and accurate financial reporting, especially for companies in the development stage.

Comparison to Industry Standards

• The restatement of financials is not uncommon in the biotech industry, particularly for companies that are rapidly growing or undergoing significant changes.
• Companies like Cassava Sciences and Prothena have also faced scrutiny over their financial reporting and data integrity.
• The level of losses and accumulated deficit is not unusual for a development-stage biotech company, but the going concern warning is a significant concern.
• The company's focus on cell therapy and immuno-oncology aligns with current industry trends, but the competition in these areas is intense.

Management Changes

Related Party Transactions

• In September 2023, the Company entered into a transaction with AG Bio Life Capital I LP (AG), a Delaware limited partnership, where an employee of the Company is the general partner. The Company agreed to issue 600,000 shares of common stock of the Company (AG Shares) to AG, in exchange for $600,000, $100,000 payable in cash and the balance payable under a promissory note (AG Note).

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the restatement and financial challenges.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers and partners may be concerned about the company's ability to deliver on its commitments.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to work to remediate the material weaknesses in its internal control over financial reporting.
• The company will continue to pursue strategic partnerships and collaborations to expand its product pipeline.
• The company will seek additional funding through public or private financings.
• The company will continue to develop its CD38-GEAR-NK and CD38-Diagnostic programs.

Key Dates

Keywords

biopharmaceutical, cell therapy, oncology, immunotherapy, clinical trials, CD38, SNAP-CAR, GEAR-NK, financial restatement, subscription receivable